Nanjing Vishee Medical Technology Co., Ltd (SHA:688580)
China · Delayed Price · Currency is CNY 44.30
+0.34 (0.77%)
Sep 4, 2026, 3:00 PM CST
SHA:688580 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,240 | 4,632 | 2,652 | 4,361 | 3,651 | 7,436 | |
Market Cap Growth | -13.56% | 74.68% | -39.20% | 19.47% | -50.91% | 7.08% |
Enterprise Value | 3,381 | 3,614 | 1,625 | 3,228 | 2,385 | 6,149 |
Last Close Price | 44.30 | 47.42 | 26.87 | 42.46 | 34.99 | 69.90 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.03 | 33.55 | 26.01 | 32.01 | 38.91 | 41.82 |
Forward PE | 25.46 | 30.38 | 15.10 | 23.98 | 20.71 | 32.77 |
PS Ratio | 8.86 | 10.01 | 6.63 | 9.44 | 11.35 | 17.29 |
PB Ratio | 2.51 | 2.74 | 1.63 | 2.68 | 2.39 | 4.85 |
P/TBV Ratio | 2.78 | 3.10 | 1.85 | 3.04 | 2.70 | 4.91 |
P/FCF Ratio | 252.18 | 79.02 | 508.83 | 6087.76 | - | 106.20 |
P/OCF Ratio | 24.76 | 26.21 | 22.42 | 32.50 | 42.37 | 47.25 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.06 | 7.81 | 4.06 | 6.98 | 7.42 | 14.30 |
EV/EBITDA Ratio | 20.51 | 22.90 | 15.75 | 24.15 | 28.81 | 38.93 |
EV/EBIT Ratio | 24.53 | 27.39 | 19.71 | 28.13 | 35.69 | 41.53 |
EV/FCF Ratio | 201.07 | 61.65 | 311.85 | 4506.06 | - | 87.81 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0 | 0.00 | 0.00 | - | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.00 | 0.01 | 0.02 | - | 0.01 | 0.02 |
Debt / FCF Ratio | 0.02 | 0.02 | 0.32 | - | - | 0.04 |
Net Debt / Equity Ratio | -0.51 | -0.60 | -0.65 | -0.71 | -0.82 | -0.89 |
Net Debt / EBITDA Ratio | -5.26 | -6.47 | -10.33 | -8.64 | -15.06 | -8.63 |
Net Debt / FCF Ratio | -51.10 | -17.43 | -204.63 | -1612.14 | 132.00 | -19.46 |
Asset Turnover | 0.27 | 0.25 | 0.22 | 0.27 | 0.19 | 0.27 |
Inventory Turnover | 3.90 | 3.88 | 3.52 | 3.99 | 2.71 | 3.21 |
Quick Ratio | 8.65 | 4.95 | 5.83 | 7.97 | 9.90 | 13.49 |
Current Ratio | 9.38 | 5.18 | 6.07 | 8.27 | 10.21 | 13.81 |
Return on Equity (ROE) | 10.20% | 8.32% | 6.27% | 8.64% | 6.13% | 12.06% |
Return on Assets (ROA) | 4.82% | 4.42% | 2.84% | 4.11% | 2.51% | 5.82% |
Return on Invested Capital (ROIC) | 14.62% | 19.15% | 14.38% | 27.67% | 26.23% | 124.12% |
Return on Capital Employed (ROCE) | 8.10% | 7.80% | 5.10% | 6.90% | 4.30% | 9.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.98% | 2.98% | 3.84% | 3.12% | 2.57% | 2.39% |
FCF Yield | 0.40% | 1.27% | 0.20% | 0.02% | -0.26% | 0.94% |
Dividend Yield | 0.24% | 0.23% | 2.98% | 2.53% | 1.40% | 1.33% |
Payout Ratio | 60.93% | 55.46% | 100.22% | 37.46% | 94.76% | 40.40% |
Buyback Yield / Dilution | 0.32% | -0.61% | 0.43% | -0.05% | 0.31% | -17.41% |
Total Shareholder Return | 0.56% | -0.39% | 3.40% | 2.49% | 1.71% | -16.08% |